AMPK-activation by Metformin in FSGS: AMP-FSGS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Epistemonikos ID: 23828dfd25dc7c793071be72f4f537283a013127
First added on: May 15, 2024